Stock of the Day - November 21, 2024

Cyclacel Pharmaceuticals (CYCC)

$6.37

$0.00 (0.0%)

Market Cap: $14.26M

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.

The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Today's Trend

Cyclacel Pharmaceuticals, Inc. (CYCC) saw heightened volatility today driven by a sharp rally fueled by retail and options activity, multiple LULD trading halts, a company statement to address the swings, and subsequent profit-taking.

The stock jumped sharply as heavy call-options flows and retail investor interest drove volume to 21.9 million shares versus a 206.9 K average, sparking a substantial uptick. Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
Cyclacel issued a notice acknowledging the price swings but confirmed there are no new material developments, aiming to reassure investors about its clinical programs. CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
Trading was repeatedly paused under the exchange’s Limit Up–Limit Down (LULD) mechanism throughout the session, reflecting extreme intraday price swings without new catalysts.
After an initial surge of over 270%, shares gave back ground as volatility concerns and profit-taking set in, leading to a notable pullback late in the day. Cyclacel stock dips after trimming 270% surge amid volatility concerns

← Previous Stock of the Day Next Stock of the Day →